Serum and blood based biomarkers for lung cancer screening: A systematic review

BMC Cancer

Volumn 18, Issue 1, 2018, Pages

  Chu, Gavin C W ^a   Lazare, Kim ^b   Sullivan, Frank ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Biomarkers; Lung cancer; Primary health care; Screening; Systematic review

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; TUMOR MARKER;

ALL CAUSE MORTALITY; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LOW ENERGY RADIATION; LUNG CANCER; PREDICTIVE VALUE; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; EARLY CANCER DIAGNOSIS; GENETIC SCREENING; GENETICS; LUNG TUMOR; MASS SCREENING; PROCEDURES; REPRODUCIBILITY;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MASS SCREENING; MICRORNAS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85042070858     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-018-4024-3     Document Type: Article

References (23)

1. Kanodra NM, Silvestri GA, Tanner NT. Screening and early detection efforts in lung cancer. Cancer. 2015;121(9):1347-56.
2. Statistics CCSsACoC: Canadian cancer statistics 2015. In. Toronto: Canadian Cancer Society; 2015.
3. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. Br J Cancer. 2016;115(9):1147-55.
4. Sozzi G, Boeri M. Potential biomarkers for lung cancer screening. Translational lung cancer research. 2014;3(3):139-48.
5. Kathuria H, Gesthalter Y, Spira A, Brody JS, Steiling K. Updates and Controversies in the Rapidly Evolving Field of Lung Cancer Screening, Early Detection, and chemoprevention. Cancers. 2014;6:1157-79.
6. Hasan N, Kumar R, Kavuru MS: Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers. Lung 2014, 192(5):639-648.
7. Usman Ali M, Miller J, Peirson L, Fitzpatrick-Lewis D, Kenny M, Sherifali D, Raina P. Screening for lung cancer: a systematic review and meta-analysis. Prev Med. 2016;89:301-14.
8. Goulart BH, Ramsey SD. Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. Oncologist. 2013;18(8):941-6.
9. Li CM, Chu WY, Wong DL, Tsang HF, Tsui NB, Chan CM, Xue VW, Siu PM, Yung BY, Chan LW, et al. Current and future molecular diagnostics in non-small-cell lung cancer. Expert Rev Mol Diagn. 2015;15(8):1061-74.
10. Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. Biomark Med. 2013;7(1):49-58.
11. Pinsky PF. Principles of cancer screening. Surg Clin North Am. 2015;95(5):953-66.
12. Etzel CJ, Bach PB. Estimating individual risk for lung cancer. Seminars in respiratory and critical care medicine. 2011;32(1):3-9.
13. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Medicine. 2013;11:168.
14. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer prevention research (Philadelphia, Pa). 2012;5(8):992-1006.
15. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, et al. EarlyCDT(R)-lung test: improved clinical utility through additional autoantibody assays. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(5):1319-26.
16. Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G, Bertolotti R, Bellomi M, Rampinelli C, Maisonneuve P, et al. miR-Test: a blood test for lung cancer early detection. Journal of the National Cancer Institute. 2015;107(6):djv063.
17. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.[Erratum appears in J Clin Oncol. 2014 May 10;32(14):1520]. Journal of Clinical Oncology 2014. 32(8):768-73.
18. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
19. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, JFR R. Audit of the autoantibody test, EarlyCDT-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung cancer (Amsterdam, Netherlands). 2014;83(1):51-5.
20. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, Fabbri A, Galeone C, Negri E, Sozzi G, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308-15.
21. ClinicalTrials.gov: Continuous Observation of Smoking Subject (COSMOS). In.; 2010.
22. ClinicalTrials.gov: Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung Test. In.; 2013.
23. ClinicalTrials.gov: Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study (BIOMILD). In.; 2016.